RxDoctor Payments Data

Jose Cobiella, PA

Internal Medicine · Homestead, FLNPI 1023228988

Payments from drug & device makers

$3,366,707in general payments, 2019–2025

Across 188 payments — averaging $17,908 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exeltis, USA Inc.$1.3M
  • Braintree Laboratories, Inc.$1.1M
  • Mylan Inc.$479K
  • Boehringer Ingelheim International GmbH$289K
  • Ionis Pharmaceuticals, Inc.$143K
  • Amgen$66K
  • plus $21K from 16 others

What the payments were for

  • Travel & lodging$1,19063%
  • Food & beverage$69737%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,366,707 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$46,054
Medicare patients
99
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$112,497
FarxigaDapagliflozin Propanediol87$76,770
TrulicityDulaglutide32$39,569
JardianceEmpagliflozin34$30,119
EntrestoSacubitril/Valsartan14$26,144
MounjaroTirzepatide23$24,234
TradjentaLinagliptin32$23,458
OzempicSemaglutide24$23,394
VascepaIcosapent Ethyl63$22,770
Tresiba Flextouch U-100Insulin Degludec26$17,132
LinzessLinaclotide21$16,945
JanuviaSitagliptin Phosphate18$16,517
Etravirine11$11,565
JentaduetoLinagliptin/Metformin Hcl16$10,484
SymbicortBudesonide/Formoterol Fumarate28$7,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$112,497132 claims
AstraZenecaFarxiga, Symbicort$57$84,283115 claims
Lilly USA, LLCTrulicity, Mounjaro$20$63,80355 claims
NovartisEntresto$130$26,14414 claims
MerckJanuvia, Janumet$17$23,96734 claims
Novo NordiskOzempic$19$23,39424 claims
Mylan Inc.Atorvastatin Calcium$478,573$3,734520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Homestead

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →